Minirin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin. It binds to V2 receptors in the kidney’s collecting ducts, prompting insertion of water channels that reabsorb water and concentrate urine. It also stimulates V1 receptors on endothelial cells, causing release of von Willebrand factor and factor VIII, which support blood clotting.

The dose of Minirin is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function, and response to therapy. Dosage adjustments are made during treatment to achieve the desired clinical effect while minimizing the risk of hyponatremia.

Minirin is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding; the decision should be made by the healthcare provider.

To order Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Minirin (desmopressin) is a selective V2‑receptor agonist, offering a more targeted antidiuretic effect than non‑selective vasopressin analogues. It has a longer half‑life and a lower risk of vasoconstriction, making it preferable for chronic management of diabetes insipidus and for haemostatic use, whereas older agents may cause more cardiovascular side effects.

Minirin should be stored at temperatures below 25 °C, in its original packaging to protect it from moisture and light. Do not store in a bathroom or near a heat source. Keep the container tightly closed and out of reach of children.

Minirin is taken orally, usually as a tablet or melt‑dose formulation, according to the prescriber’s instructions. It is typically taken with a full glass of water, and the timing (e.g., morning or bedtime) depends on the condition being treated and the desired effect on urine output.

The most serious risks include severe hyponatremia leading to cerebral edema, seizures, or water intoxication. Patients should be monitored for signs of low sodium, such as headache, nausea, confusion, or lethargy, and fluid intake should be regulated to avoid excessive water consumption.

Minirin is contraindicated in patients with known hypersensitivity to desmopressin, uncontrolled hyponatremia, or severe renal impairment that precludes safe fluid balance. Caution is also advised in individuals with a history of epilepsy, heart failure, or pulmonary edema, as they may be more susceptible to fluid overload.